Edition:
United States

Carmat SA (ALCAR.PA)

ALCAR.PA on Paris Stock Exchange

28.82EUR
23 Feb 2017
Change (% chg)

-- (--)
Prev Close
€28.82
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
5,223
52-wk High
€44.95
52-wk Low
€24.00

Select another date:

Tue, Feb 14 2017

BRIEF-Carmat FY net loss widens to 23 million euros

* Solid cash position of 31.2 million euros ($33.13 million) at December 31, 2016

Carmat withdraws initial request to resume artificial heart implants

Artificial heart maker Carmat said on Monday it had decided to withdraw its initial request to France's national drugs agency (ANSM) to resume trial implantations.

Carmat withdraws initial request to resume artificial heart implants

Feb 6 Artificial heart maker Carmat said on Monday it had decided to withdraw its initial request to France's national drugs agency (ANSM) to resume trial implants.

Carmat shares slump after France halts heart implants

PARIS Shares in artificial heart maker Carmat slumped on Thursday after France's national drugs agency ordered it to suspend further implants following the death of a patient in October.

French drugs agency suspends new Carmat artificial heart implants

PARIS France's national drugs agency said on Wednesday it had ordered artificial heart maker Carmat to suspend further implants after a fifth patient died in October.

BRIEF-Carmat H1 net loss widens to EUR 10.2 mln

* H1 total operating income 96,827 euros ($108,901) vs 2,854 euros year ago

BRIEF-Carmat announces departure of CEO Marcello Conviti

* Carmat announces the departure of CEO Marcello Conviti Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Stéphane Piat has been appointed CEO of Carmat

* Stéphane Piat, previously division vice president of Abbott in California, has been appointed CEO of Carmat

Carmat jumps after first implantation of its bioprosthetic artificial heart

PARIS Carmat's shares jumped on Tuesday after the French company announced the first implantation of its bioprosthetic artificial heart in a final-stage clinical trial.

Carmat jumps after first implantation of its bioprosthetic artificial heart

PARIS, Aug 30 Carmat's shares jumped on Tuesday after the French company announced the first implantation of its bioprosthetic artificial heart in a final-stage clinical trial.

Select another date:

More From Around the Web